(Reuters) – Viking Therapeutics Inc said on Tuesday it will begin testing its experimental obesity drug in a mid-stage trial after reporting promising early-stage data. The drug candidate, VK2735, showed up to 6% reduction in mean weight compared to placebo in a small early-stage trial, the company said in a statement. Viking also said the […]
Health
Viking Therapeutics to start obesity drug mid-stage trial
(Reuters) – Viking Therapeutics Inc said on Tuesday it will begin testing its experimental obesity drug in a mid-stage trial after reporting promising early-stage data.
The drug candidate, VK2735, showed up to 6% reduction in mean weight compared to placebo in a small early-stage trial, the company said in a statement.
Viking also said the drug was safe and well-tolerated, with majority of adverse events being mild or moderate in the 28-day study.
Shares of the drug developer rose nearly 33% to $12 in premarket trading.
(Reporting by Mariam Sunny in Bengaluru; Editing by Rashmi Aich)